Evidence map›Paper›PMID 42707615›Full record

SynthesisFrontiers in psychiatry2026

Administrative criteria in the relapse of depressive disorder: a critical appraisal.

Sara Bernal-Cueto, Fanny Cegla-Schvartzman, Enrique Baca-García

Abstract readSystematic Review
In one paragraph

Synthesis in Frontiers in psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Sara Bernal-Cueto *Department of Psychiatry, Jimenez Diaz Foundation Hospital, Madrid, Spain.
Fanny Cegla-Schvartzman *Department of Psychiatry, Jimenez Diaz Foundation Hospital, Madrid, Spain.
Enrique Baca-GarcíaDepartment of Psychiatry, Jimenez Diaz Foundation Hospital, Madrid, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Major depressive disorder (MDD) is a leading cause of disability globally, with high relapse rates. Currently, there is no standardized consensus on administrative criteria for defining relapses in MDD. Methods: A comprehensive literature search was conducted for texts published from January 1980 to April 2026. Articles were included if they described a depressive episode/major depressive episode or unipolar depression. The initial electronic search identified 4148 documents, and 51 were finally included in this review. Results: Over two thirds of the articles focus directly on relapse of MDD, either describing the overall prognosis of the disorder in various populations, the outcome of a given intervention, or the impact of certain factors. 44 of the 51 articles provide a definition of relapse based on either clinical criteria, psychometric measures or what we will establish as administrative criteria. Among those who use scales for definition there is not much uniformity. Among the administrative criteria the most cited is hospitalization, followed by changes in treatment and the need for electroconvulsive therapy. Conclusions: We suggest a conceptual model based on these criteria to define relapse in depression by drawing some preliminary conclusions: A minimum period of time from the remission of the previous episode to the emergence of what is considered a relapse is necessary, as well as the presence of at least one high-specificity criterion-hospitalization (including emergency room visit), ECT, or suicide attempt-and, in a complementary role, structured pharmacological changes that reflect guideline-based therapeutic steps.

Indexed as

administrative criteriadepressionhospitalizationrecurrencerelapse

Identifiers

PMID42707615
PMCPMC13548797

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.